60 completed, 22 recruiting, 14 unknown, 13 terminated. 40 Not applicable, 40 Phase 2, 17 Phase 1, 5 Phase 4, 2 Phase 3.
Follow this condition Literature Review of Uterine Cancer trials Research Report on Uterine Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| COQ10 and Vitamin E for Off-Target Radiation Toxicity Coenzyme Q10 Cap/Tab, Vitamin E Cap/Tab - Prostate Cancer, Uterine Cancer | Phase 1 / Phase 2 | Not yet recruiting | University of Nebraska | 200 | 2026-12-01 | 2026-10-08 |
| Radiotherapy for Gynecologic Cancer With Up to 10 Active Metastatic Lesions Routine-care metastasis-directed radiotherapy - Cervical Cancer, Gynecologic Cancer | Recruiting | Affidea Nu-med Center of Oncological DIagnostics and Therapy | 500 | 2026-10-06 | 2026-10-20 | |
| A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies KQB368 - Advanced Solid Tumors, Colorectal Cancer (CRC) | Phase 1 | Not yet recruiting | Kumquat Biosciences Inc. | 48 | 2026-05-01 | 2026-04-21 |
| Measurement of Urinary Hormones in Patients With Abnormal Uterine Bleeding to Study Uterine Cancer Progression Uterine Bleeding, Uterine Cancer | Not yet recruiting | University of British Columbia | 50 | 2026-05-01 | 2026-05-12 | |
| Cancer Loyalty Card Study 2 (CLOCS-2) Cases & Controls - Pancreatic Cancer, Colon Cancer | Recruiting | Imperial College London | 2900 | 2026-02-04 | 2026-03-25 | |
| Prognostic Role of molEcular classiFication in Fertility-sparing treAtment of Endometrial canCEr Observation only - Uterine Cancer | Not yet recruiting | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 100 | 2026-01-01 | 2025-12-23 | |
| Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer Zanzalintinib, Paclitaxel - Uterine Cancer, Endometrial Cancer | Phase 1 | Recruiting | Washington University School of Medicine | 36 | 2025-10-17 | 2026-10-13 |
| Molecular and Cellular Profiling of Uterine Lavage Collected During Gynecologic Surgery Uterine Lavage - Gynecologic Cancer, Gynecologic Disease | Not applicable | Recruiting | Stanford University | 50 | 2025-09-19 | 2025-11-05 |
| Initial Testing of a Behavioral Intervention About Genetic Services for Families at Risk of Lynch Syndrome Information Letter and Booklet, Information Letter - Cascade Testing, Lynch Syndrome | Not applicable | Recruiting | University of Alabama at Birmingham | 185 | 2025-09-15 | 2026-07-21 |
| Sample Collection for Ongoing Research and Product Evaluation Study Breast Cancer, Lung Cancer | Recruiting | Natera, Inc. | 9600 | 2025-07-21 | 2026-01-15 | |
| Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women HyperSight cone beam computed tomography (CBCT) scan, ETHOS 2.0 - Uterine Cancer, Rectal Cancer | Recruiting | Washington University School of Medicine | 11 | 2025-04-08 | 2026-09-02 | |
| Azenosertib in Uterine Serous Carcinoma: Biomarker Study Azenosertib - Uterine Serous Carcinoma, Uterine Carcinoma | Phase 2 | Recruiting | Joyce Liu, MD | 25 | 2025-03-05 | 2026-03-02 |
| GYNecologic Cancer-Related COGnitive Impairment GYNCOG - Ovarian Cancer, Endometrial Cancer | Not applicable | Completed | Northwestern University | 60 | 2025-02-07 | 2026-03-23 |
| Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin Belzutifan - Ovarian Cancer, Ovarian Carcinoma | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 32 | 2024-12-20 | 2025-11-05 |
| Evaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology Saliva sample - Gynecologic Disease, Gynecologic Cancer | Recruiting | ZIWIG | 2500 | 2024-12-05 | 2025-01-23 | |
| Enhanced Assistance During Radiotherapy for Unmet Essential Needs Standard assistance, Enhanced assistance - Bone Cancer, Brain Cancer | Not applicable | Completed | Washington University School of Medicine | 33 | 2024-10-04 | 2025-08-26 |
| Insights Into Participating in Studies for Uterine Cancer Uterine Cancer | Unknown | Power Life Sciences Inc. | 500 | 2024-09-01 | 2023-08-21 | |
| Investigations of Reproductive Cancers in Women Uterine Cancer | Recruiting | PinkDx, Inc. | 4500 | 2024-07-30 | 2026-08-17 | |
| [18F]FES PET/.CT in Uterine Cancer 18F-Fluoroestradiol - Uterine Cancer | Phase 2 | Recruiting | Abramson Cancer Center at Penn Medicine | 30 | 2024-04-05 | 2026-06-05 |
| Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy Closure of the Vaginal Cuff after Total Hysterectomy - Abnormal Uterine Bleeding, Endometriosis | Recruiting | Aesculap AG | 132 | 2024-03-19 | 2026-06-02 |
Showing 20 of 126. Sign in to see all of them.
Uterine Neoplasms (126) · Ovarian Neoplasms (62) · Uterine Cervical Neoplasms (56) · Endometrial Neoplasms (31) · Breast Neoplasms (29) · Vulvar Neoplasms (19) · Lung Neoplasms (17) · Prostatic Neoplasms (17) · Urinary Bladder Neoplasms (17) · Esophageal Neoplasms (16) · Stomach Neoplasms (16) · Colorectal Neoplasms (15) · Head and Neck Neoplasms (15) · Neoplasms (15) · Pancreatic Neoplasms (15)
Female Urogenital Diseases (126) · Female Urogenital Diseases and Pregnancy Complications (126) · Genital Diseases (126) · Neoplasms by Site (126) · Urogenital Diseases (126) · Uterine Diseases (126) · Genital Neoplasms, Female (125) · Urogenital Neoplasms (125) · Genital Diseases, Female (124) · Neoplasms (111) · Endocrine Gland Neoplasms (66) · Endocrine System Diseases (66) · Gonadal Disorders (63) · Adnexal Diseases (62) · Ovarian Diseases (62)
Paclitaxel (7) · pembrolizumab (6) · Surveys and Questionnaires (4) · Carboplatin (3) · FANG vaccine (3) · Bevacizumab (2) · CP protocol (2) · Cisplatin (2) · Hyperthermic Intraperitoneal Chemotherapy (2) · Music Therapy (2) · Radiotherapy (2) · Saline Solution (2) · 16-fluoroestradiol (1) · Aprepitant (1) · Art Therapy (1)
Memorial Sloan Kettering Cancer Center (10) · M.D. Anderson Cancer Center (5) · University of Alabama at Birmingham (5) · Dana-Farber Cancer Institute (4) · Northwestern University (4) · Abramson Cancer Center at Penn Medicine (3) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (3) · Imperial College London (3) · UNC Lineberger Comprehensive Cancer Center (3) · Washington University School of Medicine (3) · Case Comprehensive Cancer Center (2) · Duke University (2) · Genmab (2) · Gradalis, Inc. (2) · Leap Therapeutics, Inc. (2)
United States (90) · Canada (7) · South Korea (5) · Italy (4) · United Kingdom (4) · Australia (2) · Belgium (2) · Brazil (2) · China (2) · Denmark (2) · Spain (2) · France (1) · Germany (1) · Israel (1) · Japan (1)
Emma Barber, MD, MS (3) · Mark H Einstein, M.D., M.S. (3) · Hee Seung Kim, MD (2) · John M. Straughn, MD (2) · John Nemunaitis, MD (2) · Akila Viswanathan, M.D. (1) · Alexi A. Wright, MD (1) · Amadeus Hornemann, Prof. Dr. (1) · Amy Jonson, MD (1) · An KL Reyners, Prof. Dr. (1) · Andrea Mariani, MD (1) · Andrea Russo, MD (1) · Andreas Obermair (1) · Anne Blaes, M.D. (1) · Aysel Karaca (1)
PMID 22035806, PMID 22055846, PMID 23731770, PMID 24724218, PMID 29149611, PMID 30143441, PMID 30700568, PMID 30798790, PMID 31138229, PMID 31478164, PMID 33705205, PMID 33753870, PMID 33882792, PMID 34113571, PMID 35705312, PMID 35960332, PMID 36670100, PMID 36991390, PMID 37001446, PMID 37027812, PMID 37114974, PMID 37247940, PMID 37301841, PMID 37972346, PMID 37984242, PMID 38653864, PMID 39227583, PMID 39379327, PMID 39515198, PMID 39806425, PMID 40632977, PMID 41428976, PMID 42128509, PMID 42253973, PMID 42567117, PMID 42735684
2016 (2), 2019 (1), P50CA265793 (1), R00CA277584 (1), R01NR016990 (1), R21CA167800 (1), R21NR018532 (1)